Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)

被引：0
|
作者：
Ahmann, Andrew J.
Capehorn, Matthew
Charpentier, Guillaume
Dotta, Francesco
Henkel, Elena
Lingvay, Ildiko
Holst, Anders Gaarsdal
Chang, Denise
Aroda, Vanita R.
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
187-OR
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, Andrew
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Annett, Miriam
    Aroda, Vanita
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [2] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, A.
    Capehom, M.
    Charpentier, G.
    Dotta, E.
    Henkel, E.
    Lingvay, I.
    Holst, A. Gaarsdal
    Annett, M.
    Aroda, V.
    [J]. DIABETOLOGIA, 2016, 59 : S76 - S76
  • [3] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [4] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Harashima, Shin-ichi
    Sorli, Christopher
    Tsoukas, George
    Unger, Jeffrey
    Karsbol, Julie Derving
    Hansen, Thomas
    Bain, Stephen
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
  • [5] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S. -I.
    Tsoukas, G.
    Unger, J.
    Karsbol, J. Derving
    Hansen, T.
    Bain, S.
    [J]. DIABETOLOGIA, 2016, 59 : S364 - S364
  • [6] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    [J]. DIABETES, 2021, 70
  • [7] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders G.
    Annett, Miriam P.
    Aroda, Vanita R.
    [J]. DIABETES CARE, 2018, 41 (02) : 258 - 266
  • [8] Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)
    Ahren, Bo
    Comas, Luis Masmiquel
    Kumar, Harish
    Sargin, Mehmet
    Karsbol, Julie Derving
    Jacobsen, Sanja Hald
    Chow, Francis
    [J]. DIABETES, 2016, 65 : A48 - A48
  • [9] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    [J]. DIABETOLOGIA, 2016, 59 : S76 - S77
  • [10] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    [J]. DIABETIC MEDICINE, 2017, 34 : 146 - 146
12345